- Home
- / AB Science
AB Science
Stock Price
€1
2024-10-29
Market Capitalization
€65 M
2024-10-29
Revenue
€1.2 M
FY, 2025
AB Science Summary
Company Summary
- Overview
- AB Science is a pharmaceutical company that engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. Its products are developed for treating diseases in the field of cancers, chronic inflammatory diseases, and neurological degenerative disorders.
- Type
- Public
- Status
- Active
- Founded
- 2001
- HQ
- Paris, FR | view all locations
- Website
- https://www.ab-science.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Laurent Guy, Chief Financial Officer
Christian Fassotte, Global Chief Medical Officer
Alexis Bernard, Head of Veterinary Sales
Operating MetricsView all
Patients Enrolled to Date (Masitinib Studies)
6K
Apr, 2020
Patents Issued
27
Apr, 2020
Patent Applications
36
Apr, 2020
LocationsView all
1 location detected
Paris, Île-de-France HQ
France
3 Avenue George V
AB Science Financials
Summary Financials
- Revenue (FY, 2025)
- €1.2M
- Gross profit (FY, 2025)
- €978.0K
- Net income (FY, 2025)
- (€1.6M)
- Cash (FY, 2025)
- €10.2M
- EBIT (FY, 2025)
- €639.0K
- Enterprise value
- $81.8M